NCT07216859Not yet recruiting
Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI)
Source: ClinicalTrials.gov · Last updated 13 Aug 2026
Brief summary (registry, in English)
The goal of this prospective, multicenter, open-label, blinded end-point pragmatic study is to evaluate an artificial intelligence (AI)-augmented echocardiography screening approach for early detection of metabolic dysfunction associated steatotic liver disease (MASLD) and/or cirrhosis, in patients undergoing routine transthoracic echocardiograms (TTEs). The main question it aims to answer is to: 1. Evaluate notification responsiveness and rates of confirmatory testing for patients identified as high risk for having liver disease to determine whether optimized notifications increase timely confirmatory testing and treatment initiation versus standard of care assessment. 2. Compare time to diagnosis, treatment uptake, and clinical outcomes (hospitalizations, incident ASCVD, mortality) between cohorts identified as high risk by the AI algorithm and comparison groups to determine whether AI guided screening shortens time to diagnosis and increases appropriate treatment.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 2000 (estimated)
- First submitted
- 13 Oct 2025
- Start date
- Jan 2028
- Primary completion date
- Nov 2028
- Lead sponsor
- Kaiser Permanente
- Diseases
- Fatty liver disease (MASLD/MASH)
- NCT number
- NCT07216859
What you commit to
- Study type: Interventional
- Planned participants: 2000
- From Jan 2028 to the primary completion date, Nov 2028
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior liver or kidney transplant.
Other illness
- Patient unwilling to undergo prospective testing for liver disease.
Other
- Inability to consent or communicate.
- Enrollment in hospice or life expectancy so limited that additional evaluation would not be appropriate per clinician judgment.
- Clinical circumstances where immediate alternative diagnostic pathways supersede study procedures (e.g., acute decompensation requiring urgent management).
Who the study is looking for
- Adults ≥18 years.
- Underwent routine TTE within site defined recent timeframe and flagged as high risk for MASLD and/or cirrhosis by the AI model using pre specified threshold.
- Able to provide informed consent; reachable for follow up.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Massachusetts General Hospital Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| Northwestern Medicine Coordinator of this site? Confirm its status | Chicago | United States | Unknown status |
| UCLA Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
| Cedars-Sinai Medical Center Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
| Stanford Healthcare Coordinator of this site? Confirm its status | Palo Alto | United States | Unknown status |
| Kaiser Permanente Coordinator of this site? Confirm its status | Pleasanton | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.